; or (ii) the date of its publication in the list that— (I) was published under this section before the initial publication of the list under subparagraph (A); and (II) was equivalent to the list published under section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act and comprised of patents associated with applications filed under subsection (a) of this section or under this subsection. (C) Withdrawal or suspension of licensure If the licensing of a biological product was withdrawn or suspended for safety, purity, or potency reasons, it may not be published in the list under subparagraph (A). If the withdrawal or suspension occurred after its publication in such list— (i) it shall be immediately removed from such list— (I) for the same period as the withdrawal or suspension; or (II) if the listed drug has been withdrawn from sale, for the period of withdrawal from sale or, if earlier, the period ending on the date the Secretary determines that the withdrawal from sale is not for safety, purity, or potency reasons; and (ii) a notice of the removal shall be published in the Federal Register. . 3. Review and report on types of biological product patents To be listed Not later than 3 years after the date of enactment of this Act, the Secretary of Health and Human Services shall— (1) complete a review of, and formulate recommendations on, the types of biological product patents that should be included in or removed from the list required by paragraph (9) of section 351(k) of the Public Health Service Act ( 42 U.S.C. 262(k) ), as added by section 2; and (2) report such recommendations to the Congress.